Cargando…

Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma (LUSC) is a leading cause of mobidity and mortality worldwide. Recently, there was a shift in the treatment pattern of immune therapy in LUSC patients; merely a small number of patients with non-small cell lung cancer (NSCLC) at advanced stages respond well to immune che...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiaona, Tang, Yemeng, Sheng, Jueqi, Shu, Pingping, Zhu, Xiayan, Cai, Xueding, Zhao, Chengguang, Wang, Liangxing, Huang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566981/
https://www.ncbi.nlm.nih.gov/pubmed/34746153
http://dx.doi.org/10.3389/fcell.2021.761758
_version_ 1784594135390355456
author Xie, Xiaona
Tang, Yemeng
Sheng, Jueqi
Shu, Pingping
Zhu, Xiayan
Cai, Xueding
Zhao, Chengguang
Wang, Liangxing
Huang, Xiaoying
author_facet Xie, Xiaona
Tang, Yemeng
Sheng, Jueqi
Shu, Pingping
Zhu, Xiayan
Cai, Xueding
Zhao, Chengguang
Wang, Liangxing
Huang, Xiaoying
author_sort Xie, Xiaona
collection PubMed
description Lung squamous cell carcinoma (LUSC) is a leading cause of mobidity and mortality worldwide. Recently, there was a shift in the treatment pattern of immune therapy in LUSC patients; merely a small number of patients with non-small cell lung cancer (NSCLC) at advanced stages respond well to immune checkpoint blockade (ICB) therapy, and tumor mutation burden (TMB) is a valuable independent indicator of response to immune therapy. However, specific gene mutations and their relationship with TMB and tumor-infiltrating immunocytes in LUSC are still unclear. In the present paper, our team analyzed the somatically mutated genes from the ICGC (International Cancer Genome Consortium) and TCGA (The Cancer Genome Atlas) datasets and discovered that 15 frequent gene mutations occurred in both cohorts, including ZFHX4, MUC16, FLG, TP53, LRP1B, TTN, SYNE1, RYR2, CSMD3, USH2A, MUC17, DNAH5, FAM135B, COL11A1, and RYR3. Interestingly, only mutated TTN was related to higher TMB and prognostic outcomes among the 15 mutated genes. Moreover, according to the CIBERSORT algorithm, we revealed that TTN mutation enhanced the antitumor immune response. In conclusion, TTN may have important clinical implications for relevant immune therapy of lung squamous carcinoma.
format Online
Article
Text
id pubmed-8566981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85669812021-11-05 Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma Xie, Xiaona Tang, Yemeng Sheng, Jueqi Shu, Pingping Zhu, Xiayan Cai, Xueding Zhao, Chengguang Wang, Liangxing Huang, Xiaoying Front Cell Dev Biol Cell and Developmental Biology Lung squamous cell carcinoma (LUSC) is a leading cause of mobidity and mortality worldwide. Recently, there was a shift in the treatment pattern of immune therapy in LUSC patients; merely a small number of patients with non-small cell lung cancer (NSCLC) at advanced stages respond well to immune checkpoint blockade (ICB) therapy, and tumor mutation burden (TMB) is a valuable independent indicator of response to immune therapy. However, specific gene mutations and their relationship with TMB and tumor-infiltrating immunocytes in LUSC are still unclear. In the present paper, our team analyzed the somatically mutated genes from the ICGC (International Cancer Genome Consortium) and TCGA (The Cancer Genome Atlas) datasets and discovered that 15 frequent gene mutations occurred in both cohorts, including ZFHX4, MUC16, FLG, TP53, LRP1B, TTN, SYNE1, RYR2, CSMD3, USH2A, MUC17, DNAH5, FAM135B, COL11A1, and RYR3. Interestingly, only mutated TTN was related to higher TMB and prognostic outcomes among the 15 mutated genes. Moreover, according to the CIBERSORT algorithm, we revealed that TTN mutation enhanced the antitumor immune response. In conclusion, TTN may have important clinical implications for relevant immune therapy of lung squamous carcinoma. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8566981/ /pubmed/34746153 http://dx.doi.org/10.3389/fcell.2021.761758 Text en Copyright © 2021 Xie, Tang, Sheng, Shu, Zhu, Cai, Zhao, Wang and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Xie, Xiaona
Tang, Yemeng
Sheng, Jueqi
Shu, Pingping
Zhu, Xiayan
Cai, Xueding
Zhao, Chengguang
Wang, Liangxing
Huang, Xiaoying
Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
title Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
title_full Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
title_fullStr Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
title_full_unstemmed Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
title_short Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
title_sort titin mutation is associated with tumor mutation burden and promotes antitumor immunity in lung squamous cell carcinoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566981/
https://www.ncbi.nlm.nih.gov/pubmed/34746153
http://dx.doi.org/10.3389/fcell.2021.761758
work_keys_str_mv AT xiexiaona titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT tangyemeng titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT shengjueqi titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT shupingping titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT zhuxiayan titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT caixueding titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT zhaochengguang titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT wangliangxing titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma
AT huangxiaoying titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma